钠-葡萄糖协同转运蛋白2抑制剂对罗马尼亚2型糖尿病患者可改变心血管危险因素的影响。
Impact of SGLT-2 inhibitors on modifiable cardiovascular risk factors in Romanian patients with type 2 diabetes mellitus.
作者信息
Gherbon Adriana, Frandes Mirela, Dîrpeş Darius, Timar Romulus, Timar Bogdan
机构信息
Department VII Internal Medicine - Diabetes, Nutrition, Metabolic Diseases and Systemic Rheumatology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Centre of Molecular Research in Nephrology and Vascular Disease, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
出版信息
Diabetol Metab Syndr. 2024 Apr 16;16(1):85. doi: 10.1186/s13098-024-01326-8.
BACKGROUND
Modifiable cardiovascular risk factors are high blood pressure, smoking, diabetes, sedentary lifestyle, obesity, and hypercholesterolemia.
AIM
To investigate the impact of sodium-glucose 2 co-transporter inhibitors (SGLT-2i) on modifiable cardiovascular risk factors in Romanian patients diagnosed with type 2 diabetes mellitus (T2DM).
METHOD
A retrospective study was conducted on 200 Romanian patients with T2DM who were being treated with SGLT-2i, either Dapagliflozin or Empagliflozin. Collected data included demographic characteristics, such as weight, body mass index (BMI), fasting blood glucose (FBG), creatinine, glycated hemoglobin (HbA1c), abdominal circumference (AC), urine albumin-to-creatinine ratio (UACR), systolic blood pressure (SBP), diastolic blood pressure (DBP), C-reactive protein (CRP) and N-terminal pro b-type natriuretic peptide (NT-proBNP). The patients were observed for one year after being treated with SGLT-2i.
RESULTS
The mean value of FBG decreased from 180.00 mg% (IQR: 154.50-207.00) to 130.00 mg% (IQR: 117.50-150.00) (p < 0.001), and the mean of HbA1c values decreased from 8.40% (IQR: 7.98-9.15%) to 7.30% (IQR: 6.90-7.95%) (p < 0.001). We also obtained significant positive effects on body weight, i.e., the weight decreased from 90.50 kg (82.00-106.50) to 89.00 kg (77.50-100.00) (p = 0.018), BMI from 32.87 kg/m (29.24-36.45) to 31.00 kg/m (27.74-34.71) (p < 0.001) and AC from 107.05 (± 16.39) to 102.50 (± 15.11) (p = 0.042). The UACR decreased from 23.98 mg/g (19.76-36.85) to 19.39 mg/g (1.30-24.29) (p < 0.001). Initially, the median value for SBP was 140.00mmgHg (130.00-160.00), and for DBP was 80.00 mmgHg (72.00-90.00), and one year after treatment, the medium value was 120.00 mmgHg (115.50-130.00) for SBP (p < 0.001), and 72.00 mmgHg (70.00-78.00) for DBP (p < 0.001) The mean CRP values decreased from 68.00 mg/dL (56.25-80.25) to 34.00 mg/dL (28.12-40.12) (p < 0.001), and the mean NT-proBNP decreased from 146.00pg/mL (122.50-170.50) to 136.00 pg/mL (112.50-160.50) (p = 0.005).
CONCLUSION
Treatment with SGLT-2i in Romanian patients with T2DM has beneficial effects on modifiable cardiovascular risk factors.
背景
可改变的心血管危险因素包括高血压、吸烟、糖尿病、久坐不动的生活方式、肥胖和高胆固醇血症。
目的
探讨钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）对罗马尼亚2型糖尿病（T2DM）患者可改变的心血管危险因素的影响。
方法
对200例正在接受SGLT-2i（达格列净或恩格列净）治疗的罗马尼亚T2DM患者进行回顾性研究。收集的数据包括人口统计学特征，如体重、体重指数（BMI）、空腹血糖（FBG）、肌酐、糖化血红蛋白（HbA1c）、腹围（AC）、尿白蛋白与肌酐比值（UACR）、收缩压（SBP）、舒张压（DBP）、C反应蛋白（CRP）和N末端B型脑钠肽前体（NT-proBNP）。患者在接受SGLT-2i治疗后观察一年。
结果
FBG平均值从180.00mg%（四分位距：154.50 - 207.00）降至130.00mg%（四分位距：117.50 - 150.00）（p < 0.001），HbA1c平均值从8.40%（四分位距：7.98 - 9.15%）降至7.30%（四分位距：6.90 - 7.95%）（p < 0.001）。我们还在体重方面获得了显著的积极效果，即体重从90.50kg（82.00 - 106.50）降至89.00kg（77.50 - 100.00）（p = 0.018），BMI从32.87kg/m（29.24 - 36.45）降至31.00kg/m（27.74 - 34.71）（p < 0.001），AC从107.05（±16.39）降至102.50（±15.11）（p = 0.042）。UACR从23.98mg/g（19.76 - 36.85）降至19.39mg/g（1.30 - 24.29）（p < 0.001）。最初，SBP的中位数为140.00mmHg（130.00 - 160.00），DBP的中位数为80.00mmHg（72.00 - 90.00），治疗一年后，SBP的中位数为120.00mmHg（115.50 - 130.00）（p < 0.001），DBP的中位数为72.00mmHg（70.00 - 78.00）（p < 0.001）。CRP平均值从68.00mg/dL（56.25 - 80.25）降至34.00mg/dL（28.12 - 40.12）（p < 0.001），NT-proBNP平均值从146.00pg/mL（122.50 - 170.50）降至136.00pg/mL（112.50 - 160.50）（p = 0.005）。
结论
在罗马尼亚T2DM患者中使用SGLT-2i治疗对可改变的心血管危险因素具有有益作用。
Zotero 插件